Kindred Biosciences (KIN) Gets C.L. King Civerage; Sap SE (SAP) Shorts Increased By 0.98%

Among 6 analysts covering Kindred Biosciences (NASDAQ:KIN), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Kindred Biosciences has $11.0 highest and $7.50 lowest target. $9.30’s average target is -1.59% below currents $9.45 stock price. Kindred Biosciences had 10 analyst reports since November 17, 2015 according to SRatingsIntel. The stock of Kindred Biosciences, Inc. (NASDAQ:KIN) has “Buy” rating given on Tuesday, November 1 by Ladenburg Thalmann. BMO Capital Markets downgraded the shares of KIN in report on Tuesday, November 17 to “Market Perform” rating. The rating was maintained by FBR Capital with “Buy” on Tuesday, June 27. The stock of Kindred Biosciences, Inc. (NASDAQ:KIN) earned “Hold” rating by BMO Capital Markets on Monday, August 7. FBR Capital maintained Kindred Biosciences, Inc. (NASDAQ:KIN) on Tuesday, May 30 with “Buy” rating. On Friday, November 18 the stock rating was downgraded by KeyBanc Capital Markets to “Sector Weight”.

Sap SE (NYSE:SAP) had an increase of 0.98% in short interest. SAP’s SI was 4.35 million shares in December as released by FINRA. Its up 0.98% from 4.31 million shares previously. With 423,500 avg volume, 10 days are for Sap SE (NYSE:SAP)’s short sellers to cover SAP’s short positions. The SI to Sap SE’s float is 0.44%. The stock increased 0.27% or $0.3 during the last trading session, reaching $112.66. About 51,309 shares traded. SAP SE (NYSE:SAP) has risen 36.82% since December 27, 2016 and is uptrending. It has outperformed by 20.12% the S&P500.

Analysts await Kindred Biosciences, Inc. (NASDAQ:KIN) to report earnings on March, 7. They expect $-0.33 EPS, down 13.79% or $0.04 from last year’s $-0.29 per share. After $-0.29 actual EPS reported by Kindred Biosciences, Inc. for the previous quarter, Wall Street now forecasts 13.79% negative EPS growth.

The stock decreased 1.56% or $0.15 during the last trading session, reaching $9.45. About 6,030 shares traded. Kindred Biosciences, Inc. (NASDAQ:KIN) has risen 71.15% since December 27, 2016 and is uptrending. It has outperformed by 54.45% the S&P500.

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company has market cap of $266.10 million. The companyÂ’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. It currently has negative earnings. The Company’s lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Investors sentiment decreased to 2.24 in 2017 Q3. Its down 0.52, from 2.76 in 2017Q2. It turned negative, as 5 investors sold Kindred Biosciences, Inc. shares while 12 reduced holdings. 10 funds opened positions while 28 raised stakes. 18.28 million shares or 11.16% more from 16.44 million shares in 2017Q2 were reported. Vanguard Inc holds 0% of its portfolio in Kindred Biosciences, Inc. (NASDAQ:KIN) for 849,400 shares. Deutsche Bank & Trust Ag holds 0% or 210,098 shares. Amer Gp Inc Inc reported 14,118 shares. Moreover, Granite Inv Prns Limited Liability Corp has 0.05% invested in Kindred Biosciences, Inc. (NASDAQ:KIN). Jpmorgan Chase & has 0% invested in Kindred Biosciences, Inc. (NASDAQ:KIN). Eam Invsts Ltd Liability Company holds 65,487 shares or 0.07% of its portfolio. Ameritas Partners owns 1,848 shares for 0% of their portfolio. National Bank & Trust Of Montreal Can holds 0% or 40 shares. Moreover, Ajo L P has 0.01% invested in Kindred Biosciences, Inc. (NASDAQ:KIN) for 312,586 shares. 40,769 were reported by California State Teachers Retirement. Blackrock invested in 0% or 1.07 million shares. State Street holds 289,310 shares or 0% of its portfolio. Tiaa Cref Invest Mgmt Ltd Limited Liability Company owns 58,568 shares. D E Shaw has invested 0% in Kindred Biosciences, Inc. (NASDAQ:KIN). Voya Investment Mgmt Lc has 11,383 shares for 0% of their portfolio.

SAP SE operates as an enterprise application software and database firm worldwide. The company has market cap of $134.99 billion. It offers SAP HANA and SAP S/4HANA, which are in-memory computing platforms that store and process huge data, and eliminate the maintenance of separate legacy systems and siloed data; SAP BW/4HANA, a data warehouse software; SAP S/4HANA Cloud, a software-as-a-service solution that provides the scalability, ease of management, and security; SAP SuccessFactors, a suite of human capital management solutions to develop, manage, engage, and empower the workforce; SAP Concur, a travel and expense management solution; SAP Ariba, a guided buying, light enablement, and open platform solution; and SAP Fieldglass, a solution to procure and manage external workforce. It has a 31.13 P/E ratio. The firm also provides SAP Cloud Platform, an in-memory platform-as-a-service to build, run, and extend business applications; SAP BusinessObjects Cloud, a cloud analytics solution; SAP Digital Boardroom, a solution to access firm data in real time; and SAP Leonardo, a solution to digitize manufacturing, logistics, and asset management processes, as well as maintenance, consulting, and training services.